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1. Summary 
 
Multiple myeloma (MM) is a plasma cell tumor that affects the B-lymphocytes  of the 
bone marrow. The abnormal plasma cells proliferate and produce light chain 
monoclonal proteins, which may accumulate in blood or urine (historically know as 
Bence-Jones proteins). 
MM is the most common primary malignant bone tumor and the second most 
prevalent blood cancer after non-Hodgkin’s lymphoma. It generally affects patients 
around 70 years old and is found twice as often in black males. 
Myeloma cells will propagate and eventually replace normal plasma cells leading to 
extensive bone destruction, which may provoke fractures. Radiolucent “punched-out” 
lesions of the bone are typical findings. Anaemia, renal insufficiency, hypercalcemia 
and amyloidosis are a few clinical features of this disease.  
Oral manifestations of MM are infrequent. The dentist may play a key role in the 
detection of this disease since it has been reported that oral lesions have led to the 
discovery and diagnosis of the disease. The aim of this thesis is to describe three 
cases with oral manifestations and specifically review the literature on MM. The first  
case involves an 84-year-old female with multiple gingival and radiological lesions. 
The second case was a 70-year-old female patient with lingual amyloid 
manifestations that lead to the diagnosis of MM. The third case, a 41-year-old female 
with oral manifestations that led to the diagnosis of myeloma. 
Oral lesions in the first and second case were not treated as patients had deceased 
shortly after diagnosis. In the third case, the oral lesions were treated and patient 
underwent chemotherapy and two hematopoietic progenitors cells transplants. She 
was under complete remission at a 2 year follow-up. 
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2. Résumé 
 
Le myélome multiple (MM), également connu sous le nom de plasmocytome 
multiple ou maladie de Kahler, est le résultat de la prolifération monoclonale d’un 
plasmocyte tumoral dans la moelle osseuse. Il semble que le MM a été décrit pour la 
première fois au milieu du 19ème siècle par Dalrymple, Bence-Jones et MacIntyren34; 
cette époque coïncide avec le début de la révolution industrielle, l’apparition des 
colorants synthétiques et des produits chimiques organiques12,34, d’où l’idée que les 
solvants organiques, les rayons ionisants, les herbicides et des insecticides 
pourraient jouer un rôle étiologique9. Le MM est la forme la plus commune de 
néoplasme osseux et le cancer du sang le plus répandu, après le lymphome non 
hodgkinien. Il affecte généralement des personnes âgées et deux fois plus les 
hommes de race noire. Le MM est une prolifération monoclonale maligne de 
plasmocytes. Les plasmocytes anormaux se multiplient et produisent des protéines 
monoclonales que l’on trouve dans le sang ou l’urine (chaînes légères).  
Les cellules tumorales se multiplient et se substituent aux plasmocytes normaux ; ils 
détruisent l’os, entraînant éventuellement des fractures. Les lacunes peuvent être 
discrètes et donnent un aspect ostéoporotique. Le plus souvent les lésions 
radiologiques sont bien définies et donnent des images radiotransparentes arrondies 
ou ovales37. Pour près de 80 % des patients, l’atteinte osseuse se traduit par des 
lésions "à l’emporte-pièce", des fractures, une ostéoporose13. Ces lésions sont bien 
visibles sur les radiographies de profil de la voûte du crâne. Si des 
orthopantomographies étaient systématiquement réalisées, les maxillaires seraient 
probablement atteints également très fréquement77. En effet, dans les syndromes 
lymphoprolifératifs étendus comme le MM, l’atteinte des maxillaires est fréquente, 
touchant plus souvent la mandibule4 que le maxillaire car le processus 
hématopoïétique y est plus important36. 
La prolifération massive des plasmocytes monoclonaux dans la moelle osseuse 
entraîne d’autres manifestations. Les manifestations cliniques et biologiques les plus 
fréquentes du MM sont la présence d’une immunoglobuline anormale dans le 
sang, la présence de chaînes légères dans les urines, des destructions 
squelettiques avec des lésions ostéolytiques, des fractures pathologiques et des 
douleurs osseuses, une hypercalcémie, une anémie. Ils sont directement liés à la 
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prolifération tumorale, tandis que d’autres, comme l’insuffisance rénale et 
l’insuffisance cardiaque, représentent des manifestations indirectes. Une liste 
complète des signes et symptômes est présentée dans le Tabl. 177. 
 
Les manifestations buccales du MM sont peu fréquentes. Elles peuvent comporter 
des douleurs, des troubles de la sensibilité, une tuméfaction, une mobilité dentaire 
accompagnée de saignements de la gencive, des fractures osseuses et des 
tumeurs des tissus mous. Les douleurs dentaires et les paresthésies constituent 
parfois les premières manifestations de la maladie17,36. Les signes cliniques et 
radiologiques typiques sont rappelés dans le Tableau 6. Le médecin dentiste peut 
donc contribuer à la découverte de cette maladie. 
 
Après une revue de la littérature, ce travail comporte la présentation de trois cas 
avec des manifestations buccales. Le premier cas concerne une femme de 84 ans 
avec des lésions gingivales et radiologiques multiples. Le second correspond à une 
femme de 70 ans présentant une amyloïdose buccale, principalement linguale qui a 
orienté vers le diagnostic de MM. Le troisième rapporte l’histoire d’une femme de 41 
ans dont les manifestations buccales ont mené au diagnostic de MM. Dans le 
premier et le second cas, les lésions buccales n'ont pas fait l’objet de traitement 
devant la dégradation rapide de l’état général des patientes qui sont décédées peu 
de temps après le diagnostic. Dans le troisième cas, les lésions buccales ont été 
traitées et la patiente a reçu une chimiothérapie, suivie de deux greffes de cellules 
progénitures hématopoïétiques transplantées. Après 2 ans d’évolution, la patiente 
est toujours en rémission complète.  
 
Le traitement cherche à supprimer la prolifération des cellules tumorales dans la 
moelle osseuse. Le National Comprehensive Cancer Network (NCCN) a rédigé une 
liste des traitements recommandés pour le MM. Comme la maladie est incurable, les 
soins palliatifs et les mesures d’accompagnement doivent être privilégiés pour 
améliorer la qualité de vie des patients78.  
Lors de la découverte des lésions buccales, le MM est déjà souvent à un stade 
avancé, ce qui rend le traitement difficile. Parfois, on peut énucléer les lésions 
buccales, mais le plus souvent, on se contente de surveiller leur évolution pendant 
le traitement.  
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Le médecin-dentiste a aussi un rôle important à jouer dans le traitement systémique 
du MM. Selon le National Institute of Dental and Craniofacial Research, des 
complications buccales apparaissent chez de nombreux patients qui, en plus de la 
radiothérapie, ont eu une greffe de moelle (75%) ou une chimiothérapie (40%). Des 
examens buccaux réguliers permettent d’éviter ou de réduire les risques de 
complications. Le médecin-dentiste, lors de l’élaboration du plan de traitement, doit 
prendre en considération plusieurs points : réduction ou prévention des douleurs, 
stabilisation des infections buccales potentiellement dangereuses, augmentation de 
la tolérance aux traitements anti-cancéreux et amélioration de la qualité de vie.  
Chacun des trois cas rapportés est intéressant car ils présentent des manifestations 
typiques de MM. Les lésions buccales peuvent être proches ou séparées, et ne sont 
pas nécessairement liées. Dans deux des cas présentés, le MM s'est manifesté par 
des lésions de la muqueuse buccale.  
Une revue de la littérature de tous les cas publiés a été effectuées (cf. Tab. 8 et 9). 
Ces tableaux précisent la localisation et l’aspect clinique des lésions buccales en 
fonction des groupes d'âge, de sexe et de race. Il est intéressant de noter que l'âge 
moyen est bien en deçà du groupe des "70 ans et plus", maintes fois signalé. Les 
manifestations buccales du MM ne sont pas rares et elles ont mené, dans certains 
cas, à la découverte de la maladie. Les lésions ayant conduit au diagnostic sont 
rares mais bien documentées. 
Un diagnostic plus précoce pourrait être fait par une plus grande vigilance ou une 
meilleure connaissance. Les médecins généralistes sont souvent peu familiers avec 
les manifestations buccales du MM. Puisque le MM peut se manifester initialement 
dans la cavité buccale, le rôle du dentiste devient de plus en plus important étant 
donné qu’un diagnostic rapide du MM peut améliorer la réponse du patient et les 
résultats de sa thérapie. 
Il est important d'évaluer constamment l'état des patients afin de déterminer le 
traitement approprié puisque les avantages de celui-ci peuvent être insuffisants du 
point de vue de la qualité de vie des patients. 
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3. Introduction 
 
Multiple Myeloma (MM) also known as myelomatosis, plasma cell myeloma or 
Kahler’s disease31, has its origin in the bone marrow from a single malignant 
monoclonal plasma cell. It was cited34 that MM was first described in middle of the 
19th century by Dalrymple, Bence-Jones and MacIntyren and coincides with the 
beginning of the industrial revolution when synthetic dyes and organic chemicals 
were first used12,34. Exposures to organic solvents, ionized radiation, herbicides and 
insecticides have been described to possibly play a role in the etiology of the 
disease9,31. 
MM is the most common plasma cell tumor and is the second most prevalent blood 
cancer after non-Hodgkin lymphoma48. It accounts for 1 % of all malignant diseases, 
10% of haematological malignancies22,31,34 and almost 50% of all bone  
malignancies34,71. 
Although MM is a rare disease, an average of 12’000 cases per year are diagnosed 
in the United States71 and 3’000 new cases each year in the UK38. It is estimated 
that 14’400 new cases of MM were to be diagnosed in 2001 according to the 
American Cancer Society. The annual incidence is of about 3.5 per 100’0004 . In 
patients over 80 years, the incidence of the disease increases to all most 50 new 
cases per 100’000 patients per year78. 
In Switzerland, the actual incidence of MM is unknown. According to the Association 
of Swiss Cancer Registries (www.asrt.ch), the actual Age Standardized Rate per 
100'000 (European Population) for MM, is of 5,5 in males and 3,5 in females. 
The disease is unknown in childhood and very uncommon in young adults. The MM 
research foundation states that the disease rarely affects younger patients under 40 
(2% of cases) and occurs twice as often in males38. It occurs in older patients 
between 60 and 70 years old with an average age of 6213,55. The average age at 
diagnosis, is around 69 years old for women and 68 years for men78. The disease is 
frequent in persons over 50 years of age 22. Blacks are more often affected than 
Whites. 
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4. Etiology 
 
Induced cytogenetic changes in the B cells at the lymph nodes affect the precursor 
cells. Genetic abnormalities involve single or combinations of hyperdiploidy in 
chromosomes 3 ,5, 7, 9, 11, 15, 19 and hypodiploidy of chromosomes 8, 13, 14. 
The prognostic in patients with hyperdiploid myeloma cells is more favourable than 
those with hypodiploid cells. Patients with hyperdiploid myeloma lived an average of 
34 months after diagnosis, compared to 13 months for the hypodiploid group19. Sex 
chromosome X is also affected22. 
An abnormality on chromosome 13 is now known to be a prognostic factor in MM. 
The partial or complete deletion of chromosome 13 is found in 38% of patients with 
MM. It is rarely observed as a sole abnormality and has a higher incidence in the 
hypodiploid forms74. When used together with γ - 2 - microglobulin level, deletion of 
chromosome 13 is an important prognostic indicator48.  
Although the cause of this disease is unknown, risk factors were found to be 
associated with MM such as an exposure to pesticides, herbicides, benzene and/or 
radiation22,31. Workers exposed to wood dust and sheet metal have been reported 
by Fritshi et al.in 22 to have increased risks of developing MM. 
Normally plasma cells produce a variety of antibody molecules in the blood, 
reflecting the large number of infections they may be required to fight. In MM 
however, the malignant monoclonal plasma cells have the same genetic make-up 
and therefore produce large amounts of the same proteins, which are referred to as 
monoclonal proteins or paraproteins. The latter is found in 99% of cases38. An 
estimated 15 to 20 % of MM patients produce “Bence-Jones proteins” which are 
incomplete immunoglobulins known as light chain immunoglobulins48. Roughly three 
quarters of all cases produce one type of immunoglobulins and each type may show 
a slightly different pattern of disease38. The most common immunoglobulins 
produced by MM in 50% of cases is IgG. IgA is found in 20% of cases. These light 
chain monoclonal immunoglobulins are not functional and can be detected in blood 
and urine by immunoelectrophoresis.   
MM-mutated plasma cells produce large quantities of proteins. Serum protein 
immunoelectrophoresis will determine the type and relative quantity of proteins in serum 
(Fig1 and 2), which are seen as an exaggerated spike known as an M-spike. The M-spike 
represents the specific type of monoclonal immunoglobulins produced and  
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Fig 1: Relative amounts of serum protein electrophoresis of a healthy patient.  
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Fig 2: Higher than normal γ portion which represents an accumulation of 
monoclonal gammopathy referred to as the “M-spike” found in MM. 
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thus permits identification of type of the myeloma present. As the M protein 
accumulates, the amount of the immunoglobulins will increase. Any measurement of 
the immunoglobulins whether it be immunofixation or deduction from 
electrophoresis, will sum up both the relative to normal and malignant 
immunoglobulins. Individual analysis of the specific immunoglobulin would be 
necessary to determine its exact quantity. Most MM specialists follow the course of 
the disease with this curve28. It is the relative change and form of the SPEP graph 
that is of interest rather than the component values. 
There is a MM variant found in very few cases, less than 1% of MM48, known as 
“non-secretory myeloma” (NSM) in which the malignant plasma cells do not produce 
the abnormal monoclonal immunoglobulin proteins (paraproteins) that are 
characteristic of the disease. The blood and urine are therefore void of myeloid or 
light chain immunoglobulines. Following the evolution of the disease is difficult, as 
relative amounts of immunoglobulins appear normal. Bone marrow biopsy and 
aspirates as well as magnetic resonance imaging are efficient tools in assessing this 
type of myeloma. In NSM, patients are spared some of the consequences of the 
presence of excess protein that is a hallmark of MM. However, usual proliferation of 
malignant plasma cells in bone marrow also lead to lytic bone lesions and crowding 
out of normal cells.  
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5. Physiopathology 
 
The principle symptoms include inflammation, bone pain, anaemia and fatigue. The 
massive proliferation of long lived monoclonal plasmocytes in the bone marrow 
cause the major clinical symptoms of MM36. 
Weight loss, asthenia and fever are general symptoms37. Most patients (roughly 2/3) 
experience back or chest pain rather than in extremities. The pain is accentuated 
and precipitated by movement29,31. An inclusive list of signs and symptoms are 
described on Table 177. 
 
 
 
 Tab 1: List of signs and symptoms found in patients suffering from 
MM77. 
 
  Age 50 yrs and over are affected 
  Pain in lower lumbar region with a band-like distribution around the body 
  Pain which worsens in a suspine position 
  Bone and joint pain which worsens at night or awakens patient at night 
  Bone pain which is not relieved by conventional medication 
  Fatigue, weakness 
  Loss of weight 
  Fracture of bones (eg.dorsal and lumbar vertebrae) 
  Skeletal deformities (eg.sternum and rib cage) 
  Shortening of the spine (loss of height) 
  Neurological symptoms 
  Carpal tunnel syndrome 
  Orthostatic hypertension, headaches 
  Anhydrosis 
  Diarrhea 
  Impotence 
  Malabsorption 
  Macroglossia 
  Congestive heart failure 
  Exudative macular detachment, retinal haemorrhage 
  Bleeding and bruising 
  Repeated bronchopneumonia attacks 
  Fever of unknown origin 
  Susceptibility to herpes zoster, generalized varicella and other infections 
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There is a correlation between increased serum concentrations of carboxyl-terminal 
telopeptide of type I collagen and bone alkaline phosphatase associated with bone 
pain and fractures18,31.  
The mass of myeloma cells inhibit the production of oxygen carrying red blood cells. 
The reduced number of erythrocytes along with a renal insufficiency and resulting 
decrease in the production of erythropoietin will provoke fatigue and anaemia. The 
high Ca blood level causes fatigue, sleepiness, loss of appetite and constipation. 
Fatigue is often accompanied with cutaneous and mucosal haemorrhage due to 
defective platelet production. Bleeding disorders may result from blood 
hyperviscosity, inhibition of clotting factors by myeloma proteins and due to 
secondary thrombocytopenia. 
The inflammatory state of MM may also contribute to the anemia. Anemia and 
neutropenia result from the proliferation of the invading plasma cells in the bone 
marrow. The impaired (humoral defense) plasmocytes as well as neutropenia will 
both weaken the immune response and therefore increase susceptibility to 
infections13 as normal blood cell precursors are replaced by the proliferating plasma 
cell producing leucopenia, anemia as well as thrombocytopenia66. According to 
Kearns29, 25% of patients will suffer from recurrent infections such as infected 
urinary tracts. Gram-negative organisms as well as Streptococcus pneumoniae, 
Staphylococcus aureus, Hemophilus influenza are frequent pathogens found in 
recurrent infections31,78.   
The susceptibility is also increased by neutropenia caused by plasma cell infiltrations 
granulocytes being the first line of defense against candidal infections. 
MM is often a painful disease resulting from bone fractures due to the destruction of 
the bone matrix by the uncontrolled proliferation and synthesis of the plasma cells. 
These cells produce cytokines, which stimulate osteoclastic activity which lead to 
localized bone destruction.  
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Fig 3 : Interleukin-6 (IL-6) network in MM. IL-6 is an important growth factor for 
myeloma cells and is secreted by stromal and mononuclear cells. There is a 
“positive feedback loop” from TNF and IL-1 thus increasing secretion on IL-
678.. 
 
A complex network of lympho-hematopoietic growth factors and cell surface 
molecules govern the proliferation, differentiation and function of the lympho-
hematopoietic cells (Fig 3)26.  
Myeloma cells in culture produce cytokines such as hepatocyte growth factors 
(HGF), which stimulates these osteoclasts to produce IL-11 thus activating 
osteoclastogenesis28. Other cytokines such as IL-1 and TNF may potentiate this 
reaction. IL-6 induces B cells to differentiate into plasma cells and acts as a growth 
factor for MM by stimulating cell division and even prevents apoptosis26,48. The MM 
also produces vascular endothelial growth factors (VEGF) that promote 
angiogenesis. These growth factors are the life-support system for the pathogenesis 
of the disease. 
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A plasma cell tumor may arise as single or unifocal solitary plasmacytoma and may 
evolve into MM14,71. The clinical features are directly related to the proliferating 
process itself as well as the indirect effect of substances released by the myeloma 
cells. The tumors vary in their degree of malignancy. The proliferation of plasma 
cells involves 10% of the bone marrow in MM and may be found in any bone, the 
most common site being the spine (25 to 60%)71. The term MM refers to spread of 
the disease through the bone marrow and at multiple sites of the bone at the time of 
diagnosis. 
According to Hallek et al.26, there is a genetic progression from a normal plasma cell 
to the MM. The karyotypic instability starts with a monoclonal gammopathy of 
undetermined significance (MGUS), which results in acquired immortality, and 
seems to progressively become malignant MM26. MGUS may however remain 
stable for life or provoque amyloidosis. MGUS cells may also transform into 
intramedullary myeloma where they do accumulate and cause bone damage. 
MGUS requires observation and treatment should begin at the disease’s 
progression. Extramedullary myeloma is the next step where the transformed cells 
propagate in other extramedullary sites or in the blood causing plasma cell 
leukemia. The final transformation is into the myeloma cell line, which may be 
propagated in vitro. MM will develop in 25 % of patients with MGUS10. Patients with 
MGUS or smoldering myeloma have considerably longer survival rates38. Tab 2 
shows the differential diagnosis of other monoclonal gammopathy than MM22.  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 12
 
 Tab 2: Basic differences between MM and other monoclonal gammopathies22. 
 
  MGUS (monoclonal gammopathy of  
  undetermined significance) 
 
 
  M proteins <3 g/dl 
  <10% plasma cells in bone marrow 
  urine M proteins, anemia, hypercalcaemia, renal insuff. and 
  bone lytic lesions are all not present. 
  SMM (smoldering multiple myeloma) 
 
 
  M proteins >3 g/dl 
  >10% plasma cells in bone marrow 
  anemia, hypercalcaemia and renal insufficiency 
  are all not present 
  PCL (plasma cell leukemia) 
 
 
  traces of M proteins 
  >20% plasma cells in peripheral blood 
  young patients, bone lesions and hematological disturbances
  SP (solitary plasmacytoma) 
 
 
  presence of solitary tumor without bone lesions, urine or 
  serum abnormalities 
  WM (Waldenstrom macroglobulinemia)
 
 
  IgM, M proteins 
  hyperviscosity, extensive bone marrow plasma cell infiltra- 
  tions 
  HCD (heavy chain disease) 
 
 
  M proteins with incomplete heavy chain  
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5.1 Bone lesions 
 
Osteolytic lesions appear, as there is no new bone synthesis71. The lack of bone 
synthesis and reparation by osteoblasts often give an impression of osteoporosis. 
The lesions have well-defined borders with round or oval radiolucencies37. About 
80% of patients are diagnosed with fractures, osteoporosis and lytic so called 
"punched out" lesions13. The latter are well seen in profile radiographs of calvaria 
and are painless37. The lytic skeletal lesions in MM are spheroid in shape with 
sharply defined smooth borders and void of trabeculae. The absence of bone 
remodelling and size of lesions in MM are used as a differential diagnostic in 
comparing metastatic cancers. Rothschild et al.65 described the radiological clues 
used to distinguish MM lytic lesions from those of other metastatic carcinomas. 
The radiological bone grading system for MM patient is listed on Tab 322. 
Vertebral fractures are common and may lead to a loss of 10 cm in height per 
year31,78. Neurological complications may result from extramedullary plasmacytoma 
compression of spinal cord and affects 5 % of patients31.  
Magnetic resonance imaging and computed tomography are used to identify 
epidural involvement, tumor mass and spinal cord compression.  Magnetic 
resonance imaging has become the preferred examination in evaluating bone 
lesions of vertebrae. 
 
 
 
  Tab 3 : Radiological bone grading system in MM22. 
 
  Grade 0 :     Normal radiograph 
  Grade 1 :     Extensive osteoporosis or osteopenia 
  Grade 2 :     Osteolysis 
 
 
 
 
 
     The early radiographic lesions are rarely painful36. Osteolytic lesions are often found 
in bone with high haematopoiesis such as ribs, lumbar spine and pelvic bone. 
Calvaria, sternum, clavicles, proximal portions of the humerus and femur as well as 
occasionally mandible (younger patients) also have important haematopoiesis 
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making them ideal for myelomatous infiltrates58. Hands and feet are therefore rarely 
involved. MM is also occasionally associated with extraskeletal lesions in lymph 
nodes, liver and spleen. 
Bones become fragile and prone to fracture36. Twenty percent of cases have 
fractures13. In the ribs, MM appears as expanded costal lesions or as soft tissue 
masses.  
As MM is 4.5 to 12.1 times more common in patients with AIDS compared to the 
general population, young patients with poorly characterized (anaplastic) myeloma 
cells and difficult immunophenotyping should be tested for HIV55. Pouli et al.55 
reported a case of a 34-year-old patient whose first manifestation of AIDS was MM.  
 
 
 
5.2 Solitary plasmacytoma 
 
Solitary and extramedullary plasmacytomas are unusual and separate distinct 
entities7. In order to qualify as a solitary plasmacytoma, there has to be a disease-
free period of at least 3 years to separate cases of MM with isolated solitary lesions 
(50 % survival rate in MM patients within 2 years of diagnosis )8. A positive biopsy, 
an absence of other lesions, less than 5% of bone plasma cells in bone marrow and 
absence of light chain immunoglobulins are all criteria that are necessary to 
establish the presence of a solitary plasmacytoma. The latter is found in the oro-
pharynx, naso-pharynx, sinus, larynx as well as other anatomical sites such as the 
stomach, intestine, bladder, central nervous center, thyroid, testis, lungs, parotide, 
lymphatic ganglions and skin. 
In the oral cavity plasmacytoma is a well-defined unilocular or multilocular osteolytic 
lesion that is usually located in the premolar and molar region. Three to seven 
percent of plasma cell neoplasms are solitary plasmocytomas which when 
adequately treated have a better prognosis than MM. Present thought is that solitary 
plasmacytoma evolves into MM7. According to Keith et al.in11, 50% of 
plasmacytomas and medullary  plasmacytoma will progress to MM in 3 to 5 years. 
Medullary plasmacytomas have more of a tendancy to evolve into MM. George et 
al.22 stated that 55% of solitary plasmacytomas eventually progress to MM. 
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5.3 Systemic amyloidosis 
 
Amyloidosis is an extracellular amorphous eosinophilic infiltration of abnormal 
proteins, which arises idiopathically or as a complication of MM.  
All tissues and organs may be affected including the oro-facial district. Amyloid 
accumulation compromises the physiology of organs and thus impairing their 
function and therefore patient survival. Amyloidosis should not be considered a 
single disease but rather as a group of diseases having in common the deposition of 
similar appearing proteins9. It is a rare affection, may be present early in the 
evolution of MM and often has a poor prognostic. There is a 15% risk of developing 
amyloidosis in patients suffering from MM. 
For the diagnosis of amyloid, aspiration of the subcutaneous abdominal fat and 
biopsy of rectal mucosa are done. Other useful biopsy sites are the minor salivary 
glands. The gingiva, nerve, skin, kidney and liver may also be biopsied. 
Amyloid is a homogeneous, highly refractile substance with an affinity for Congo red 
dye under polarized light microscopy. Under electron microscopy, amyloid consists 
of 100 Å (10 nm) linear nonbranching fibrils and has a cross-β pattern under X-ray 
diffraction43. 
The fibrillary component of amyloid is the basis of amyloid classification53. There are 
many forms of amyloidosis, which are derived from a particular protein precursor. 
The classification of amyloid is based on the composition of the deposits, or on its 
etiology. Regardless its origin, the amyloid is made of three elements: a protein part 
which differs according to the type of amyloidosis, a glycosaminoglycan portion 
consisting of a glucidic and glycoprotein part and a P component which is common 
for most amyloid affections. Grateau et al.24 have reviewed the classification of the 
different types of human amyloid proteins and their precursors. 
 
The mechanisms that lead to the formation of amyloid deposits are not completely 
understood. It seems that many types of cells intervene in the formation of amyloid 
such as the endothelial-reticulate system and plasma cells. The latter was proven 
as amyloid fibrils were found to be synthesized intracellularly in the plasma cells53. 
Amyloid fibrils are derived from Light chain monoclonal immunoglobulins in MM 
patients. The deposits of primary amyloidosis are commonly associated with 
plasmocytomas. Tissue receptors react with light chain proteins forming insoluble 
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amyloid deposits in connective tissue anywhere in the body. Many types of amyloid 
have a systemic distribution and give rise to various PO symptoms of the three 
principal types of amyloid. The first type, which has an N-terminal sequence that is 
homologous to a portion of the variable region of an immunoglobulin light chain, is 
called AL (Amyloid Light chain). The second type occurs in patients with secondary 
amyloidosis and has a unique N-terminal sequence of a non-immunoglobulin protein 
called AA protein. The third type is a prealbumin molecule with a single amino acid 
substitution that is associated with familial amyloid polyneuropathy. There are also 
hereditary type amyloidosis characterized by a peripheral sensory and motor 
neuropathy24. 
AL amyloid occurs in primary amyloidosis and is strongly present in amyloidosis 
associated with MM. It is the least frequent type of amyloid and has an incidence of 
9 cases per million per year24. Primary amyloidosis is related to the high 
accumulation of lambda light chains. At diagnosis of amyloidosis, 80% of patients 
have detectable light chain of which only 20% have MM. 
AL amyloid is more frequent in men. The tongue, thyroid gland, intestinal tract, skin 
and heart are involved in primary AL amyloidosis. Amyloid is deposited in soft 
tissues, parenchymatous organs (liver, kidney and spleen), vascular systems, 
intestines, autonomic nervous system and especially myocardium in which it 
interferes with their function as extensive deposits may cause structural damage to 
the concerning organ (results in functional damage as structure dictates 
function)66,71. Conduction defects, congestive heart failure, mal absorption and renal 
failure may therefore result. Biopsy of affected tissues is stained with Congo red, 
giving an apple green appearance with polarized light (see Fig 16). Thioflavine T 
staining of specimen is also strongly positive. 
Peri-ocular sub-cutaneous purpura and macroglossia are highly significative of 
amyloidosis24. Other signs including carpian canal syndrome, peripheric neuropathy, 
restrictive cardiomyopathy and high levels of albumin are all manifestations that 
should merit further investigation for amyloid AL24. 
Yvanyl in24 reported that AL amyloid is present in 10% of MM. According to Epstein, 
focal or disseminated amyloid deposited is found in 7 to 20 % of patients with MM. 
Raubenheimer mentions that 6 to 15% MM patients have amyloid complications and 
described a case report where the most prominent feature of the disease was 
extensive oral and perioral amyloidosis57. 
 17
Systemic amyloidosis has a ‘poor’ prognosis13. Amyloidosis associated with MM has 
the poorest prognosis, as death within 1 year is common43. The survival rate of a 
patient diagnosed with amyloidosis is only of 4 months and indicates a worsening 
prognosis66,77. Arrhythmias and intractable heart failure due to myocardial 
amyloidosis are the most common causes of this high mortality rate.  
Systemic AL amyloidosis is treated with a combination of prednisone and melphalan, 
which has limited results. Surgical interventions are often indicated in 
gastrointestinal amyloidosis, esophageal infiltration or obstruction or perforation and 
bleeding of intestines as well as macroglossia42. When possible, transplantation of 
autologous hematopoietic progenitors cells (AHPC) seem to be the most efficient 
treatment in keeping amyloidosis under control as there is a regression of both the 
lesions and  symptomatology. 
 
 
 
5.4 Durie and Salmon classification of MM 
 
The Durie and Salmon classification system (Tab 4) is based on the M protein 
levels, number of lytic bone lesions, serum calcium and haemoglobin levels. It helps 
to determine prognosis, treatment options and when to begin therapy25. Certain 
categories do not have to be treated immediately thus allowing the patients own 
immune system to contain disease. This also avoids side effects and complications 
associated with chemotherapy.  
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 Tab 4 : Salmon and Durie staging classification of MM25 . 
 
 
  Stage I (all the following criteria are present): 
  hemoglobin > 10g/ dl 
  normal calcium levels (< or = 120mg/l ) 
  isolated plamacytoma or normal bone 
  low level of monoclonal immunoglobulines (IgG<50g/l, IgA<30g/l, urine Ig  
  <4g/24h) 
  an estimated low level of myeloma cells (<0.6 x10¹²/m²) 
 
  Stage II (none of the criteria of stage III and most of the criteria for stage I).  
 
  intermediate level of myeloma cells (0.6-1.2x10¹²/m²) 
 
  Stage III (at least one of the following criteria) 
 
  haemoglobin <8.5 g/dl 
  calcemia >120mg/l (3mmol/l) 
  multiple osteolytic lesions with or without bone fractures 
  high level of immunoglobulins (IgG>70g/l,IgA>50g/l, urine Ig>or = 12g/24h) 
 
  Subclassification:    A: normal renal function (creatinine<20mg/l),            
                                  B: anormal renal function (creatinine > or = 20mg/l.  
 
 
 
 
5.5 Laboratory findings 
 
Fine needle aspiration of the bone marrow is the most conservative approach in 
diagnosing MM. Should there be no presence of fluid, the possibility of a vascular 
lesion may be ruled out. MM may be diagnosed by the presence of atypical plasma 
cells within osteolytic bone lesions. The plasma myeloma cells are ovoid clusters of 
small cells that have abundant amorphous basophilic cytoplasm with an eccentric 
nucleus. The chromatin is dispersed at the periphery of the nucleus in a “cart-wheel” 
fashion.  
Systemic bone scans such as magnetic resonance imaging or computerized axial 
tomography, serum protein immunoelectrophoresis, complete blood count, 
urinalysis, histological examinations of bone marrow and soft tissue biopsy are all 
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used to diagnose MM36,48,77. Tab 5 lists the more important laboratory findings in 
MM. 
 
 Tab 5 : Laboratory findings in MM. 
 
  Renal insufficiency, elevation in total plasma proteins 
  Augmented alkaline phosphatase 
  Increased erythrocyte sedimentation rate (ESR>100) 
  Increase in C-reactive proteins (CRP) 
  Hypoalbuminemia 
  Reversed albumin/globulin ratio 
  Normocytic, normochromic anemia in 2/3 of patients which will 
  ultimately occur in all patients , pancytopenia 
  Rouleau formation in peripheral blood smear 
  Anormal morphology of plasma cells 
  Abnormal coagulation   
  Decreased platelet formation 
  Low level of factor VIII 
  Monoclonal hypergammaglobulinemia with immunoparesia 
  Hypercalciuria and hypercalcemia 
 
 
 
Renal filtration of large quantities of immunoglobulins causes damage to the kidneys 
leading to renal dysfunction. Renal impairments, hypercalcemia and hyperurcemia 
are associated with advanced stages of the disease13. Renal failure occurred in 25 
to 28 % of patients22,29,38. Circulating immunoglobulins cause renal tubular damage 
and amyloid deposits57.  
Renal insufficiency is often found and may be one of the first manifestations of MM 
in older patients. It may be caused by amyloidosis, hypercalcemia, pyelonephritis, 
inadequate use of contrast products for radiological examinations, or precipitated 
monoclonal light chains that obstruct the distal and collecting tubules causing 
myeloma kidney. The “myeloma kidney” is unable to filter the serum creatinine 
which may increase to 2mg/dl (177 mmol/l)31.  
Ill-explained acute or subacute renal failure should be an “alarm bell” for myeloma 
kidneys.  
Immunoperoxidase is used to establish the monoclonal nature of plasma cells in 
tissue biopsy by identifying the immunoglobulins in the cytoplasm.  
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The most common MM immunoglobulins produced are IgG or IgA with the presence 
of kappa or lambda light chains.  
The electrophoresis of urine and/or serum shows an important presence of a 
monoclonal M protein in most patients. According to Kyle31 , a study among 1027 
MM patients  showed that 51.5 % had IgG, 21 % had IgA and only 16 % light chain 
were present. 
Sedimentation rate (>100) and protein levels (>60 g/l) are increased37,44. Diagnosis 
is usually obtained with punction biopsies of the posterior iliac spine. Although 
sternum punctures are avoided due to bone fragility, they may reveal >30% of 
plasma cells (normal 5%)11,37. Bone marrow aspirates show 15 to 90% of myeloid 
cells according to Meyer et al.44. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 21
6. Oral and maxillofacial manifestations 
 
Lesions in the jaws are uncommon in that plasma cell tumors account for a small 
percentage of head and neck malignant tumors22. Literature is mostly based on case 
reports or small series of cases. 
Pain, numbness and swelling, mobility of teeth accompanied by bleeding, bone 
fracture, soft tissue tumors are all oral manifestations of MM. Toothaches and 
paresthesia of the mental nerve may also lead to the discovery of the disease17,36. 
When swelling or odontogenic pain is present without normally associates infection 
or trauma, a neoplastic origin should be ruled out. A case was reported where an 
osteolytic lesion on a vital, non-carious tooth #48 mimicking a periapical cyst, was a 
fortuitous finding and revealed MM11. 
A 29 year-old women consulting her dentist for a non-inflammatory painful 
mandibular swelling and mobile tooth with a usual “salt and pepper” radiological 
appearance of underlying bone was diagnosed as having MM4.  
Another case was described where a patient who had consulted for a mobile tooth 
which later allowed the diagnosed as a solitary plasmacytoma in the molar region of 
the mandible7.  
It is in the late stages of the disease that bone lesions are found in the mandible at a 
prevalence rate varying from 5.18 to 28.8%13. 
Reiboiras-Lopez et al.61 reported a clinical case where the first manifestation of MM 
was a loss of feeling on the right lower vermillion, pain and mobility of tooth #48. 
Paresthesia of the lower lip was due to the compression of the alveolar nerve at the 
mandibular angle or infiltration of the nerve by the tumor. Ramon et al.56 reported 
another case of MM manifesting itself by a numbness of the lower lip, pain and 
swelling of the left mandible. Mandibular osseous lesions are variable and may be 
mistaken for radicular cysts, ameloblastomas, or metastases7. 
According to Finkel-Tapiero et al.16, oral mucosal lesions often appear as a red-violet 
or skin colored nodule measuring between one to five centimetres in diameter. He 
also stated that they sometimes have either a tumoral, plaque or even ulcerated 
appearance. The intraoral lesion may also present itself as a gingival swelling with a 
rough and eroded surface that bleeds easily51. If levels of plasma proteins are high 
(ESR>100), the hyperviscosity of the blood can reduce blood flow and cause 
abnormal bleeding of gums when brushing38. 
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The oral lesions are often associated with advanced osteolytic lesions that are 
accompanied by deep bone pain, mobility of teeth, gingival bleeding, root resorption  
and mandibular expansion36. Oral lesions resulting from extention of underlying MM 
bone lesions have not been formerly described and are often similarly related to 
secondary distant cutaneous metastases of MM bone lesions16. Mandibular 
radiographic lesions are never an isolated finding and are only observed in patients 
with skull and other osteolytic lesions22. 
In a literature review of 783 patients, oral mucosal lesions were rare (less than 14% 
of cases)13. The authors concluded that this estimate was probably low as material 
from medical records lacked oral or dental examinations as well as absence of 
radiographs.  
Maxillofacial involvement is quite common. Reported occurrences of oral lesions in 
MM vary from 2 to 70%21. One third of radiological cases involve the jaws, which 
may be the first bony manifestation of MM56. It was reported that the lower jaw was 
affected twice as often as the upper71.   
Systematic radiographs have been reported to reveal an incidence up to 30%11,76. 
Typical mandibular radiographic lesions are bone fractures, external root resorptions 
and radiolucent osteolytic lesions with radiodense margins. According to Gonzalez, 
the first manifestations of MM occur in the oral cavity and jaws in 13 to 15% of 
cases23. The mandible is affected more frequently than the maxilla.  
Lesions are multicentric although solitary lesions may be present for months or 
years before a generalized involvement is seen56. 
Another case report was described where radiographic lesions were found in the 
anterior maxilla with a fracture of the pterygoid process. It was stated that oral 
manifestations are present in about 14 to 30% of cases13.  
Myeloma cells may even infiltrate the condyle presenting itself as temporo-
mandibular joint (TMJ) dysfuntion or facial asymmetry. TMJ lesions (tumors) are rare 
and are to be differentiated from condylar hypertrophy, benign tumors, malignant 
tumors and condylar involvement of systemic diseases. Gonzalez et al.23 described 2 
cases where the chief complaint was a pain and dysfunction syndrome. A consistent 
radiological image was present in both cases. The lesion was a diffuse ill-defined 
radiolucent image affecting the condyle. 
The most common maxillofacial involvement is found in the posterior third of the 
mandible near the ramus13. Two cases were described where a pathological fracture 
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of the mandibular angle leads to the discovery of MM22. At the Mayo Clinic, out of 
814 patients, 24 had maxilla involvement and 13 had mandible involvement41. 
 
 Tab 6 : Typical clinical signs of lesions in MM. 
 
  Pain 
  Swelling expansion of jaw  
  Mobility or migration of teeth, root resorption 
  Paresthesia of lower lip 
  Gingival tumor or soft tissue masses 
  Pathological fractures, radiolucent lesions 
  Hemorrhage 
Amyloidosis (macroglossia with tongue indentations, purpura  
etc.), 
  often diffuse or local nodules of tissue, or raised plaques. 
 
 
Raubenheimer58 described expansion of jaws by a myeloma. Although rare, 16 out 
of 59 cases studied by Bruce and Royerin39 had jaw manifestations in areas of higher 
hematopoiesis (premolar and molar region and ramus). Tamir at al.71 cited that none 
were found in a study of 25 patients by Brinch et al.  with solitary plasmacytoma. 
Anecdotally a few rare cases of oral hairy leukoplakia have been reported in 
association with hematological malignancies3. Oral hairy leukoplakia, which is 
usually associated with HIV, has been observed in a HIV-negative patient suffering 
from MM3. The lesions appeared 2 weeks after chemotherapy (VAD). This is indeed 
not really surprising because OHL is the result of an impairment of the immune 
system, which allows a localized expression of the Epstein-Barr virus. 
Kaposi’s disease has also been associated with MM. Only seventeen cases have 
been reported 6. There is an unclear link between HHV8, Kaposi’s disease and MM.  
 
A list of articles used with relevant data can be found in Tab 7. Note that a similar 
chart in Tab 8 shows the equivalent information regarding solitary plasmacytoma as 
it is known to be a precursor of MM. These tables show localizations and 
macroscopic descriptions of oral lesions at various age, sex and race groups. It is 
interesting to note that the mean age of patients diagnosed with MM is well under 
the often quoted “above 70 years of age”. Perhaps increased vigilance or knowledge 
allows for earlier diagnosis. Oral lesions leading to the diagnosis of MM are 
uncommon but well documented. The three cases reported here showed known oral 
and maxillofacial manifestations of MM.  
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Tab 7 : Localization and macroscopic description of oral lesions of MM in various  
age, sex and race groups reported by above authors. 
 
 Authors 
 
Sex/Age 
  /Race 
Localization and description of MM lesions 
 
 
 Finkel-Tapiero N16 M/69/W Violet palatal exophytic mass 
 Epstein J B et al. 13 F/53/W Blue-red smooth soft tissue mass in tuberosity 
soft to palpation 
 Chindia M L4 F/29/W Soft painful tissue mass over right body of mandible 
with mobile right molar 
 Raubenheimer E J58 M/70/W Painful mandibular teeth associated with rapidly enlarging swelling  
from tooth 45 to angle of the left jaw 
 Lee C.P36 M/55/? Pink, firm, smooth surface with central ulceration that was painful and 
progressively enlarging mass in lower posterior edentulous ridge 
 Lee C P36 F/53/? Pink, rubbery consistency painful gingival swelling with reddish borders  
in left lower premolar region with slight enlargement of mandible 
 Kearns G J30 F/88/B Pulsatile, soft swelling of the left side of the palate associated with tooth 
Mobility and numbness of lower left lip 
 Dhanrajani P J11 M/55/B No oral lesions associated with periapical lesion 
 Ramon Y56 F/66/W Painful swelling of left side of mandible associated with numbness of lower 
lip without oral mucosal lesions 
 Bloomgren J3 M/56/? Oral hairy leukoplakia 
 Shearn M A68 F/71/W Sjögren’s syndrome (fissured tongue, dry mouth) 
 Schlesinger I67 M/49/W Oral amyloidosis 
 Terpos E72  F/71/W Sjögren’s syndrome  
 OtaT50 F/49/W Sjögren’s syndrome  
 Tabachnick T70 M/75/W Bluish, fluctuant, apparently fluid-filled masses on maxillary molar and  
canine area 
 Reboiras D61 F/60/? Anaesthesia of right lower hemilip as first sign, mucosa normal 
 Ozaki M51 M/39/? Swelling mass with rough surface located on the gingival in the mandible 
left molar region. The lesion was eroded and bleed easily. 
 Miyoshi I45 M/73/? Macroglossia due to amyloidosis of the tongue 
 Raubenheimer E J59 F/66/? 
M/34/? 
F/60/? 
M/60/? 
M/40/? 
M/55/? 
M/60/? 
Amyloidosis of the tongue 
          “ 
          “ 
          “ 
          “ 
          “ 
          “ 
 Raubenheimer E J57 M/25/B Oral and perioral amyloidosis, macroglossia 
 Salisbury P L66 W/64/B Exophytic lesion of the buccal mucosa in the bite plane, amyloid deposits 
on lateral side of tongue 
 Flick W G17 M/64/B Raised, white, non tender lesion on both lateral borders of tongue and  
buccal mucosa. Lesions were on a line parallel to the occlusal plane. 
results revealed oral amyloidosis 
 Mardinger O42 W/53/? Macroglossia due to primary amyloidosis 
 Kraut R A31 W/50/? Amyloidosis (multiple soft nodules of oral surface of the upper lip and 
macroglossia) 
 Reinish E62 M/65/W Amyloidosis (macroglossia) and jaw deformity 
 Meyer I et al.44 ? Amyloidosis (macroglossia) and purpura 
 Furutani M et al.21 F/83/? Multilocular osteolytic lesion with pathological fracture 
 Mozaffari E et al.46 M/55/W Progressive intraoral swelling with extensive bleeding from minor oral 
surgical procedure 
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 Van der Waal R73 F/ /? 
M/67/? 
F/82/? 
F/50/? 
F/80/? 
F/62/? 
F/66/? 
F/77/?  
F/73/? 
 
Amyloidosis (swelling of floor of mouth) 
Amyloidosis (indurated tongue and floor of mouth) 
Amyloidosis (macroglossia) 
Amyloidosis (tongue nodules and ulcerations) 
Amyloidosis (macroglossia) 
Amyloidosis (macroglossia) 
Amyloidosis (indurated tongue,floor of mouth and buccal mucosa) 
Amyloidosis (macroglossia,swelling of gingiva and buccal mucosa) 
Amyloidosis (macroglossia,swelling of floor of mouth) 
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Tab 8 : Localization and clinicoradiological features of solitary plasmacytoma in  
 various age, sex and races as reported by above authors. 
 
 Authors 
 
Sex/Age/ 
  /Race 
 
Localization and description of solitary plasmacytomas 
 Zachariades N77 M/64/? Extended hard swelling of right cheek with slightly anemic  
overlaying mucosa and hyperesthesia of the Right mental nerve 
 Loh H S39 M/36/C Non tender swelling in the 32 to 42 region, no abnormality 
in overlying soft tissues 
(retrospective evaluation of 23 reported cases with above case) 
M/76/W Painless progressive swelling of lower left lip 
M/57/W Painful swelling of the right side of the tongue, periods of  
hypesthesia of inferior alveolar nerve, asymmetrical  
appearance of the face. Bilateral bulging mass with rubberlike 
consistency  covered by smooth tender, dark mucosa. 
 Tamir R  et al.71 
W/68/W Rubbery consistency covered with smooth pink mucosa on  
lower left ridge 
 Laurent F et al.35 M/58/ ? Swelling mass in lower right ridge affect comfort of denture 
 Collangettes D et al. F/56/ ? Swelling mass in buccal gingival crest associated with an  
Ulceration 
 Lambert F et al.34 M/42/ ? Enlargement of mandibular mass situated between the left 
canine and third molar 
M/70/W Painful raised ulceration around right and left body of mandible 
adjacent to teeth 36 and 37 as well as 46 and 47 
F/79/W Red raised asymptomatic swelling of left maxillary vestibule 
F/40/W Swelling on right mandibular ridge with tendency to bleed 
F/72/W Red ulcerated raised lesion on left anterior mandible 
F/68/W White, red, painful ulceration on maxillary gingiva 
F/82/Asian Painful firm mass on left mandible body and angle 
F/73/W Painful raised swelling on right maxillary vestibule and alveolus 
F/59/B Pain at apices of teeth 46 and 47 
M/68/W Pain associated with right posterior mandible adjacent to 46 
M/52/W Red raised painful swelling of right posterior mandible 
F/66/W Asymptomatic radiolucency at apices of teeth 35 and 36 
M/73/W Asymptomatic extraction site of tooth 37 
 Pisano J J et al.54 
M/57/W Raised expanding swelling of right maxillary alveolar ridge  
adjacent teeth 15 to 12 
 Khochtali H et al.30 M/24/? Swelling of right upper buccal vestibule covered by normal  
mucosa 
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6.1 Oral amyloidosis in MM 
 
Oral amyloidosis may be present as an early sign at the beginning of the disease or 
as a later complication. Oral amyloid manifestations are present in 39% of 
amyloidosis cases5. There is a clinical diversity in the oral manifestations of amyloid. 
Localized asymptomatic oral deposits of amyloid form yellow, firm, elastic nodular 
masses that vary in size between a few millimeters to half a centimeter53. The 
amyloid deposits affect the appearance of the lips as they become thick, pale and 
the keratinized outer portion may have an irregular border. 
 
Macroglossia, growth of nodular masses on lips and submandibular salivary glands 
are oral manifestations that affect about 40% of patients42,62. An estimated 25% of 
cases have lingual involvement according to certain authors53,77. A case study of 54 
patients by Reinish et al.62 reported that primary amyloidosis associated with MM 
affected the tongue in all cases, 5.4% in salivary glands, 3.6% of buccal mucosal, 
1.8% of gingival, lip and temporal mandibular joint. 
The tongue and salivary glands may be infiltrated by amyloid causing xerostomia13.  
Accumulations of infiltrated amyloid nodules in deeper portions of the tongue also 
result in a loss of elasticity and mobility. It renders speech, swallowing (dysphagia), 
mastication and even keeping mouth closed difficult due to protrusion of the tongue. 
Constant drooling results42,52. The tongue may have a pale, and occasionally red 
color. Ulcerations associated with bullous hemorrhages may be present. Masticatory 
traumas provoke these hemorrhages, which may lead to painful ulcerations with 
yellow raised borders53. 
Reinish et al.62 stated that the first clinical signs of primary amyloidosis might be 
macroglossia with tooth indentations along the lateral border, resulting difficulties in 
closing mouth and an open bite62. Flick et al.17 described a case where a 64-year-old 
black man was diagnosed to have MM from an intraoral soft tissue lesion and 
amyloidal macroglossia.  
Cutaneous amyloidosis may be present as nodules, papules, diffuse mass or even 
as bullous lesions. Other cutaneous manifestations include subcutaneous 
hemorrhages caused by vascular infiltrations that accompany amyloid substances. 
Clinically it presents itself as a subcutaneous hemorrhage, which is easily provoked 
 28
by minor trauma. These hemorrhages are often localized on the inner canthus, 
forehead, naso-genian sulcus, pavilion of the ear or on the periphery of the mouth. 
 
Although it is impossible to determine which patients will have amyloid deposits, 
there is a higher incidence in light chain diseases66. Death often occurs mainly due 
to complications from amyloidosis and not MM66.  
Oral amyloidosis should be regarded as a possible paraneoplastic marker of MM 
making a biopsy mandatory in patients that are unknown to have any association 
with underlying plasma cell dyscrasia62,73.  
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6.2 Pseudo-Sjögren syndrome 
 
Sjögren syndrome is a chronic autoimmune disorder, which involves the infiltration of 
B-lymphocytes in exocrine glands that lead to the destruction of lacrimal and salivary 
glands thus resulting in xerostomia and xerophthalmia50. Although it is associated 
with many autoimmune diseases as lupus erythematosous, polymyositis, systemic 
sclerosis and rheumatoid arthritis, the connection with MM is rare.  
Schlesinger67 reports a case where amyloidosis associated with MM, infiltrated and 
replaced major and minor salivary glands resulting in xerostomia, which mimicked 
Sjögren syndrome. Amyloidosis can be mistaken for a variety of oral affections and 
often occurs in MM. According to Schlesinger67, myeloma amyloidosis should be 
considered in xerostomia when histopathological and serological evidence of 
Sjögren syndrome are absent. 
Since benign gammapathy is linked to Sjögren syndrome and may result in a 
malignant lymphoproliferation such as MM, there should be, and it is astonishing that 
there is not, a higher incidence of Sjögren associated with MM50,76. 
Shearn68 described a case where a 71-year-old patient presented herself with 
anaemia and strong back pain. MM was diagnosed. According to the past medical 
history, Sjögren syndrome was present prior to MM. As the association is 
uncommon, it may merely be coincidental or there may an immunological aberration 
that may have lead to the emergence of the disease. 
Rodriguez-Cuartero64 reported a case of a 65-year-old patient presented herself with 
xerostomia and xerophthalmia. Further investigations revealed a monoclonal spike in 
the gamma region of the serum which was identified as IgG with 
immunoelectrophoresis, osteolytic lesions and a 22% plasma cell infiltration that 
confirmed diagnostic of MM. 
Another case report described a 49-year-old female patient suffering from for seven-
year case history of Sjögren and benign IgGλ monoclonal gammopathy that led to 
MM after 7 years51. 
Presently investigations are being done on whether the chronic inflammation present 
in Sjögren may affect, or stimulate the development of MM.  
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7. Treatment and evolution 
 
The treatment of MM aims at suppressing the proliferation of the myeloma cells in 
the bone marrow. The National Comprehensive Cancer Network (NCCN) has listed 
official recommended treatment therapies for MM48. 
Over the last three decades, there has been little success in the treatment of MM 
despite the use of many different chemotherapeutic agents such as melphalan, an 
alkylating agent, and prednisone. The association of both drugs still remain a 
standard reference treatment that has been used for the last forty years27.  
Although mephalan and prednisone are considered to be standard therapy for over 
thirty-five years, the median survival period is up to 2 and half years75. 
Chemotherapy induces response in half of cases with a median response rate time 
of about 2 years according to the Moffit cancer center10. 
Chemotherapy consists of an induction, maintenance and, relapse and reinduction 
phase if required.  
Irradiation therapy is also used to hinder progression of the disease. Cures have not 
been documented in MM patients48. Radiation therapy is mainly used with or without 
chemotherapy for solitary plasmacytomas48. Lee36  described a case where a stage II 
MM patient underwent systemic chemotherapy and local radiotherapy of an initial 
mandibular soft tissue mass lesion, which subsequently resolved. A second mass in 
the maxilla was later found, however the patient died of sepsis shortly after36 . 
Patients with active stage II and III or refractory MM are treated with chemotherapy. 
The conventional chemotherapy in patients older than 70 years is given in cycles 
and is administered for a year or until the disease is stabilized. Systemic 
chemotherapy usually controls oral lesions36. 
The continuous daily perfusion of the VAD IV (vincristine, adriamycine, 
dexamethasone) result in a remission in 60% of patients37. There is a 50% response 
rate after 2 years in patients treated by this type of chemotherapy. In randomized 
clinical studies, it was noted that an unusual number of patients had complete 
remission or at least a prolonged response after having an AHPC transplant. The 
conclusion of these results established that the standard treatment of patients under 
65 years old consisted of 3 or 4 cycles of VAD followed by one or two autologous 
grafts. The VAD regimen is effective in melphalan and prednisone therapy resistant 
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patients75 and may be a more beneficial regiment when used in special cases such 
as patients with renal failure.  
 
Salvage chemotherapy for refractory MM, includes the use of cyclophosphamide-
VAD, etoposide/dexamethasone/ara-C-cisplatin (EDAP) and high dose 
cyclophamide48. 
Complete remission is rare (3%) and in general, the association of other agents to 
melphalan and prednisone were disappointing as the survival rate was not 
significantly improved12. A clinical response of a 50 % reduction in M protein levels is 
considered to be satisfactory21. Total cure is extremely rare22. In a case report by 
Tabashnick and Levine70, the oral manifestations of MM seemed to disappear after 
the chemotherapy treatment without any recurrent lesions in a 75 year old man. 
 
It is during refractory periods or relapses that patients are at risk and should be 
closely monitored to avoid threatening degradations of the patients health78. The 
major cause of treatment failure is relapse.  
Patients are also vulnerable to systemic fungal infections and Pneumocistis cariini 
after chemotherapy3. The frequent use of prednisone and chemotherapeutic agents 
further weaken the immune response easing recurrent bacterial infections.  
Stable forms of MM known as “smoldering myeloma” may not require treatment 
however monoclonal protein levels should be monitored closely. Unstable MM 
requires immediate treatment that is based on the patients medical history, general 
health, laboratory tests, stage of disease and symptoms48. 
 
Cytokines such as interferons are used to try and improve survival by increasing 
treatment response. Interferon-α (IFN-α) is used in most clinical trials. The response 
of chemotherapy is apparently increased following IFN-α22. Wada et Mizogucchi75 
reported that IFN-α therapy with an alkylating glucocorticoid-agents regimen gave 
higher response rates but similar survival rates. It is not recommended for initial 
chemotherapeutic treatments and is not regularly used asides for maintaining a 
response in non-evolving MM. Interferon-γ (IFN-γ) inhibits IL-6 growth dependant MM 
without effect on endogenous IL-626. It is active as a single agent in recurrent or 
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unresponsive MM to conventional therapies as well as in newly diagnosed disease 
but has a lower response rate than standard chemotherapy. 
   
Recent advances in preventive care of bone destruction with biphosphonates, of 
anemia with erythropoietin or G-CSF for treatment related myelosuppression, are all 
advances in supportive care of myeloma patients. These treatments are however not 
of routine use27. 
AHPC transplants accompanied by high-dose therapy prolongs survival rate and 
increases response rates51,75. Only a small proportion of allogenic transplanted 
patients are cured, most patients suffer relapses and there is a high morbidity related 
to graft-versus-host disease69. High dose melphalan chemotherapy accompanying 
stem cell transplantation is rather used in younger patients47. The tolerance of elderly 
patients to combinations of aggressive treatments is low. Specific medical 
requirements for these treatments are necessary41.  
Desperate cases require intensive chemotherapy with high doses of Alkeran® IV 
accompanied with or without total body irradiation. This will lead to neutropenia 
requiring a bone marrow autograft37. The 2000 annual meeting of the Swiss Society 
of Internal Medicine stated that in the last 15 years the main progresses were 
observed in intensive hematopoetic stem cell autograft treatment27. It was concluded 
that these grafts were not a curative agent and that future hopes remain with 
intensive associative drug therapy and new approaches with biphosphonates, 
thalidomide or immunotherapy. 
 
To help prevent renal insufficiency, the regular intake of alkaline water (i.e. Vichy) 
reduces precipitation of light chain immunoglobulins37,38,48.  Occasionally, supportive 
care consisting of withdrawing blood from the patient and removing the M proteins 
(plasmapheresis) is performed especially when symptomatic hyperviscosity is 
feared.  
 
Viruses, oncogenes, adhesion molecules as well as cytokines such as IL-6 and IL-1β 
all seem to be related to the pathogenetic progression of MM8,26,32. IL-6 is an 
important paracrine and autocrine growth factor in the development of MM cells as 
well as in bone resorption51. Present research on immunotherapeutic approaches 
target the interception of an IL-6 signal51.  
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A clear understanding of the pathogenesis will provide new insight in the treatment 
possibilities of MM. 
The reactions in the microenvironment resulting from the bone resorptions may be 
important to the proliferation of the MM as when bone resorption is inhibited by 
bisphosphates, the progression of the disease is decreased27,32. The biphosphates 
inhibit osteoclastic activity thus ultimately limiting fractures and reduces the 
hypercalcaemia37. Another biphosphate called palmidronate has been approved for 
treating bone metastases. Biphosphates also reduce myeloma cell growth, inhibit 
angiogenesis and thus increase tumor cell death48. The rate of radiological 
examinations is influenced by the patient symptomatology. According to Tabachnick 
and Levine70 , regular radiographic examination should be done every 9 months to 
assess evolution of MM upon it’s diagnosis.  
A variety of osteoclastic stimulation factors have recently been identified and have 
lead to the clinical trials of new bone resorbtion inhibitory agents such as 
osteoprotegerin and Rank-Fc. The latter both inhibit key interactions between the 
MM cells and osteoclasts2. 
 
Patients complaining of severe back pain, paresthesia of lower extremities or bowel 
dysfunction should be considered as a medical emergency and require immediate 
magnetic resonance imaging and a full follow-up to avoid further neurological 
damage such as paraplegia. These patients should take extra-precaution not to put 
themselves at risk of falling48. 
It is relevant that the quality of life of the patient be regularly determined before and 
after treatments. Supportive therapies such as biphosphonates, growth factors, 
intravenous immunoglobulins and antibiotics are relievers of complications of the 
disease. 
 
As the disease is incurable, supportive and palliative care is important in patient 
management to improve quality of life78. Patients are advised to stay active to favour 
osteosynthesis.  Back braces, orthopaedic support and palliative medication are 
beneficial. Pathological bone fractures may require surgery. 
Primary analgesics are inefficient in the therapeutic treatment of bone pain 
associated with MM35. Occasionally low dose radiation therapy is used to relieve 
uncontrollable bone pain and spinal cord compression48. New supportive care called 
 34
vertebroplasty is under evaluation to help relieve back pain. It consists of injecting 
acrylamide cement into damaged vertebrae. 
 
Administering erythropoietin has been found to increase hematocrit in 50 % of 
patients and reduces required transfusions. New supportive care consists of weekly 
injections of novel erythrocyte stimulating protein which may prevent anaemia by 
stimulating red blood cell formation27. 
Low counts of white blood cells are elevated with growth hormones (colony-
stimulating factors) such as filgrastim and sargramostim 48. 
 
Thalidomide well known for its teratogenic effect, has recently been used as an 
inhibitor of angiogenesis and an immune stimulant in the treatment of MM. It reduces 
the blood flow to the tumour leading to an intratumoral hypoxy33. 
Clinical studies state that thalidomide is a single-agent salvage therapy in treating 
refractory MM and in combination with dexamethasone (20 to 40 mg/day for 4 
consecutive days, 1 to 2 times a month) for smouldering or active MM48. It is the first 
drug to extend the survival rate by 1 or 2 years in refractory MM12,17.  
Frequent side effects of this drug include constipation, sleepiness, fatigue, skin 
dryness, oedemas of lower extremities and dizziness15. The principal risk is its 
toxicity to the peripheral nervous system that is dose-dependant. The Food and Drug 
Administration (FDA) as well as France’s Medication Agency (AM) both recommend 
birth control throughout the treatment as well one month after and three months after 
(AM) respectively33. It would seem unlikely that MM patients would consider 
pregnancy. Men are recommended to practice birth control until 3 months after 
treatment. 
Thalidomide is presently still being tested in association with standard chemotherapy 
or after hematopoietic stem cell autografts27. At the VIII International Myeloma 
Workshop (May 2001), it was concluded thalidomide (200–400 mg/day) is an 
established therapeutic option in the treatment of MM patients and will continue to be 
useful in the management of these patients18. Less toxic derivatives of thalidomide 
as well as proteasome inhibitors 26S (bortézomide) are also being used. 
Other drugs such as immunomodulators, 2-methoxyestradiol, neovastat and arsenic 
trioxide are all being tested in therapies for MM47. 
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Clarythromycin and dehydroepiandrosterone (DHEA) are presently also being tested 
and evaluated as a new preventative therapy to stop early stage myeloma from 
evolving into full-blown MM.  
A proportion of patients treated with AHPC transplants seem to get cured more 
because of the adoptive immunotherapy (graft vs myeloma), rather than from the 
intense post-graft curative therapy. 
 
 
7.1 Treatment of oral amyloid lesions 
 
There is presently no cure available for neither systemic amyloidosis nor its oral 
manifestations. Treatments are based on reducing pain and discomfort. Accessible 
amyloid deposits of the oral cavity, pharynx and larynx are conservatively excised66. 
The surgical management of macroglossia had resulted only in short-term 
improvement as the condition had rapidly returned to preoperative state, and even 
worsened. It was concluded that there are factors affecting surgical intervention in 
macroglossia that should be closely evaluated and that the patients should be 
prepared for the unpredictable postoperative results42. 
In cases of reduced salivary flow, the mucosa should be closely monitored for signs 
of candidiasis and rampant caries. Conventional therapies such as the regular use of 
bicarbonate mouthwashes, artificial saliva and fluoride trays are beneficial. Less 
invasive measures such as occlusal adjustments, proper adaptation of 
prostodontics, nutritional counseling and regular monitoring of macroglossia should 
be considered62. Regular oral examinations by the dentist and visits to the dental 
hygienist are important to reduce or help eliminate all sources of inflammation of the 
soft tissues that may arise due to modifications of oral mucosal (growth of amyloid 
nodules). These lesions are often painless but are sources of supplementary 
functional nuisance. 
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7.2 Survival rate 
 
MM is usually fatal. Patients succumb to anemia, bone marrow depression and 
intermittent infections. The median survival rate is approximately 3.5 years after 
diagnosis and roughly 5% of patients will survive over 10 years9. One report stated 
that all five patients examined died within 28 month of diagnosis of MM22. 
Although MM is incurable, the survival rate is based on the present stage of the 
disease. The outcome of the disease is related to the tumor burden and its 
proliferation, which may be qualified by the Durie-Salmon staging system (Tab 4). 
The tumor burden is based on the values of immunoglobulins, M spike, bone 
involvement, etc. and are all indicators of the activity of MM. 
The Durie-Salmon staging system (Tab 4) is based on renal function as well as 
tumor burden in patients suffering from MM. The rate of survival can be estimated by 
the Durie-Salmon staging system, which is of 38 months in stage I, 26 months in 
stage II, 19 months in stage III36. This staging system helps determine the 
aggressiveness and prognostic of the disease. There is however no direct 
correlation to the response of treatment78. The evolution of the disease is associated 
with these 3 stages. The Durie-Salmon staging system remains a standard to which 
new prognostic and staging systems are referred and compared25. 
 
Other clinical and laboratory findings such as β2-microglobulin, plasma cell labeling 
index, chromosome deletion of 13q and 17p, lactate dehydrogenase and bone 
marrow microvessel density, all are indicators that help determine extent, evolution 
and response to treatments48. 
Chemotherapy prolongs survival between 3 to 5 years11,13. MM prognostic depends 
on the importance of tumour mass (reflected by levels of serum β2-microglobulin), its 
chemosensitivity as well as the state of the renal insufficiency37. The degree of 
hypercalcemia, hyperuricemia and myeloma nephrosis are also factors that affect 
the pronostic77.  
Bone pain and fracture are significantly correlated with higher concentrations of 
carboxy-terminal of type I collagen (ICTP) and are associated with higher Durie-
Salmon stages and reduced survival32. 
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There are higher rates of kidney failure, lower serum M component, higher 
associates amyloidosis and light chain excretion rates with patients suffering from 
IgD myeloma as opposed to IgG or IgA myeloma32. 
 
There is no significant differences in survival rate with patients treated with 
melphalan and prednisone versus those treated with alternating cycles of  
vincristine, cyclophosphamide, melphalan and prednisone22. 
There is an increased survival benefit with high dose therapies and autologous stem 
cell support. Durie12 stated that high dose therapy has a response rate of 50% in 
symptomatic myeloma patients.  
Survival rates are also related to the histological patterns of biopsies such as 
plasmocytic, mixed cellular or plasmoblastic types24 . 
 
 
7.3 Patient management 
 
Once oral lesions have been biopsied, close monitoring will be necessary during 
cancer therapies.  
The role of a dentist may extend its importance in the outcome of systemic cancer 
treatment in MM. According to the National Institute of Dental and Craniofacial 
Research, complications arise in most radiotherapy patients in 75 % of bone marrow 
transplants and 40 % of chemotherapy patients49.  
In a study by Furman et al.20, the overall infections among patients were 7 to 15 
times greater than regular hospitalized control patients. Infection risk is greater in the 
first two months after chemotherapy. 
Oral complications due to chemotherapy or radiation may have serious 
consequences on patient’s health and planned cancer treatments. Tab 9 shows 
prophylactic steps that should be taken before cancer therapies. 
The oral cavity is an important port of entry for systemic infections. Preexisting and 
untreated oral infections can complicate treatment therapies in cancer patients. The 
effects and consequences of systemic and local cancer treatments of the oral cavity 
are well known and will not be treated in detail in this thesis .  
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Tab 9 : General prechemotherapy and preradiotherapy prophylaxis  
 In cancer patients. 
 Identification and treatment of existing infections, problematic teeth, oral mucosal 
 affections 
 Stabilization or elimination of potential infections (extractions to avoid potential 
 osteonecrosis) 
 Prosthodontic evaluation  
 Oral surgery at least 2 weeks prior radiotherapy and 7 to 10 days prior 
 chemotherapy  
 Provide dietary counselling 
 Individual oral hygiene regimen (supplemental fluoride trays for head and neck 
 radiotherapy) 
 Regular follow-up oral care /every 4-8 weeks for the first 6 months 
 Removal of orthodontic bands and brackets if in radiation field or should highly    
 stomatotoxic chemotherapy be used 
 
 
 
Oral surgery or important dental treatments should be performed at least 7 to 10 
days before myelosuppresion.  Quality of life and patient survival are improved by 
adapting oral care before, during and after cancer treatments. Madeya et al.40 
describe the pathophysiology and secondary complications in cancer therapy. 
Myelosuppression caused by chemotherapy and cancer treatments both alter the 
integrity on the oral tissues. The outcome of the latter is an increased risk of oral 
complications. Mucositis / stomatitis expose oral mucosal to viral, bacterial and 
fungal infections which result from side effects of chemo and radiotherapy of 
underlying structure.  
Decalcifications and rampant dental caries are lifelong risks that are direct effect of 
xerostomia caused by radiotherapy and may begin within 3 months of completing 
radiotherapy. 
Asides removal of bone sequestrae in osteomyelitis as a consequence of depressed 
immunity, surgery has few indications in the treatment of MM lesions within the jaw 
as surgery can only be considered as a palliative procedur42,58. Small lesions may be 
excised and arc plates or metal cap splints may be necessary to unite fractured 
bone ends. The latter will minimize patient discomfort. 
Secondary complications of MM (renal failure, infection and anemia) may lead to 
rapid deterioration of patient’s prognostic. With a median survival rate of 2 to 3 
years, surgical options should therefore be well though over in respect to patient’s 
response to radiation therapy, chemotherapy and resulting quality of life.  
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In many cases, treatments of oral lesions were under investigation or simply 
supervised without treatment as patient had shortly deceased thereafter5,22,36,51,57,77. 
As the treatments of oral manifestations of MM are restricted, the dental team should 
put emphasize on avoiding oral complications resulting from cancer therapies (Tab 
9). 
The presence of oral lesions usually coincides with advanced stages of MM36. A 
survey of 388 patients of which 69 underwent dental extractions showed that these 
interventions in the prechemotherapy and pre-bone marrow transplant time frame 
where however not detrimental or harmful to the medical outcome of the patient60. 
Whether a difficulty in eating due to stomatitis, tissue fibrosis (trismus), loss of 
appetite due to functional disabilities or taste alterations, poor nutritional habits will 
develop and affect general health. 
The dental team is an important screening filter for all patients about to undergo 
cancer treatments. Regular oral examinations, evaluation and close supervision are 
the absolute prerequisite to avoid risk and extended of oral complication in cancer 
patients. It is beneficial in determining treatment plan, reducing or preventing oral 
pain, stabilizing potentially dangerous oral infections, increasing tolerance to 
complete cancer treatment and improving quality of life. Acute and chronic dental 
infections may be eliminated and treated successfully with either endodontia or 
extractions. It is essential that the MM oral lesions be identified as early as possible 
in order to start treatment and thus increase patient’s prognostic. Local oral biopsies 
may allow initial diagnosis leading to further investigation into potential systemic 
diseases. 
A literature review of sequelae and complications of dental extractions in patients 
undergoing hematological cancer treatments was done by Raut et al.60. He stated 
that the removal of active infected teeth is controversial because of associated risks 
of bleeding and infection, which may result in delaying systemic treatments. The 
literature revealed however few reports of the latter and concluded that dental 
extractions can be safely performed in patients with hematological malignancies. It 
was concluded that when proper precautions are taken, complications are rare as 
opposed to other studies that reported a high rates of complications60.  
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8. Case report 
 
 
8.1 First case 
 
Mrs. D. M., an 84-year-old patient was referred to the Division of Stomatology and 
Oral surgery of University of Geneva dental school (Prof. J. Samson) in June 1996 
for the diagnosis and treatment of tumoral lesions of the palate and buccal gingiva. 
The patient past medical history revealed a IgG type MM stage IIIA, with severe 
multifocal osteolytic lesions and numerous bone fractures. The patient was 
hospitalized in orthopedics for a broken tibia and fractured right forearm (Fig 4). 
During the patient’s hospitalization, she benefited from palliative radiotherapy for 
residual pain from anterior shoulder fracture. Upon return to home, the patient was 
unable to care for herself as moving became difficult. The patient was then 
hospitalized for further care.  
The patient suffered from hypertension, chronic pain, chronic constipation and poor 
bladder control. She had lost her vision from her left eye with a recent decrease of 
vision in her right eye. 
Other findings: no retrosternal pain, dyspnea, orthopnea or palpitations. Small 
oedema on left foot. No sign of respiratory insufficiency. 
The patient was under the following medication: MST® 2x20 mg/d, Prednisone® 
5mg/d, Reniten®10mg/d, Zantic nocte® 300mg/d, Spasmo-Urgenine® 3x 1cp/d, 
Seresta® 15 mg/d, Dienoestrol ortho®crème 2x/week, Sandoglobulines® every 6 
weeks, Tructosan® . 
Radiographic examination revealed multiple fractures of long bones with multiple 
osteolytic lesions. Frontal and saggital X-rays showed typical punched out lesions 
calvaria (Fig 5 and 6). The orthopantogram (Fig 7) demonstrated a radiolucency     
apical of teeth 44 and 45 (Fig 9) which would correspond with the buccal mass seen 
on Fig 8.  
Oral cavity examination showed that there were three nodular painless masses 
present in the fibromucosa. A lesion was present on the left tuberosity overlapping 
the palate (Fig 10 and 11), two other lesions were present on the buccal region of 
tooth 43 and between teeth 33 to 34 (Fig 9). A two centimetres in diameter biopsy of 
the left tuberosity was performed.  
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The histopathological examination of the mucosal fragment revealed a normal 
stratified squamous epithelium covered by a thin ortho and parakeratinized surface 
layer. The superficial corium was heavily infiltrated by lymphocytes and tumoral 
plasmacells whereas the deeper segments were purely plasmacytic (Fig 12, 13 and 
14). The plasma cells had a certain degree of anisonucleosis accompanied with high 
degree of mitosis. There were signs of cell necrosis. Amyloidosis was not present. 
The infiltrates were well vascularized, with numerous extravased red blood cells 
present. Tumoral cells were also present within the lumen of certain vessels.  
A immunohistochemistry study (Fig15 and 16) revealed a monoclonal plasmacytic 
infiltrate consisting of IgG with λ light chains. IgA, IgM and Κ light chain tested 
negatively. The final diagnosis was extramedullary type IgG myeloma. 
At diagnosis of the palatal and buccal lesions, the patient’s general health had 
quickly deteriorated which hindered the importance of further treatment of oral 
lesions. The patient deceased shortly after. 
 
 
                   
 
 
Fig 4 :  Radiograph of front right fore arm showing fracture of radius. MM cells 
            in bone marrow cause osteolytic lesions which renders bone fragile 
            and leads to increased fractures. 
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Fig 5 : Saggital view of calvarium. Note typical “punched-out “ osteolytic  
           lesions. 
 
 
                                   
 
 
 
 
Fig 6 : Frontal radiograph. Note typical osteolytic “punched-out” lesions. 
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Fig 7 : Note radioopacity on upper left tuberosity equivalent to mucosal lesion.                       
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Fig 8 : Mass located on vestibular gingival between teeth 43 and 44. 
 
 
 
 
 
 
 
Fig 9 : Detail of ill-limited radiolucency extending from periapical area of teeth 43  
           and  45. Note also the diverging root of 43 and 44. 
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Fig 10 : Exophytic mass on left tuberosity representing oral location of MM. 
               
 
 
 
 
 
 
 
Fig 11 : Detail of upper left tuberosity showing underlying lesion. 
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Fig 12 : Low magnification of the gingival biopsy showing MM cell infiltration 
             (HES, x4). 
 
 
                  
 
Fig 13 : Medium magnification showing tumoral plasma cells within the 
             lumen of a vessel (HES, x10). 
 
 
 
                   
 
Fig 14 : Higher magnification showing the tumoral plasma cell morphology 
             (HES, x40). 
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Fig 15 : Strong cytoplasmic positivity for the lambda chain 
              (immunoperoxidase, x20). 
 
 
 
 
                        
 
Fig 16 : Negative staining for kappa chain (immunoperoxidase, x20). 
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8.2 Second case 
 
Mrs J. D., a 70-year-old woman was addressed to the Division of Stomatology and 
Oral surgery of the Geneva University School of Dental Medicine (Prof. G. Fiore-
Donno) in 1983 for lingual lesions that had been evolving over the last few months. 
Asides a parotidectomy twenty years before, the patient was in good general health  
until 1980 when she was treated for hypertension. In 1981, she was hospitalized for 
bilateral carpal tunnel syndrome and in 1982 for cardiac insufficiency. 
The patient had been suffering from a progressively enlarging tongue which lead to 
functional disability that interfered with speech and swallowing. Clinical examination 
revealed a discrete enlargement of the submandibular glands, papulo-ecchymotic 
lesions around the internal canthus (Fig 17). The submucosal hemorrhage had 
decreased noticeably after 3 days however similar lesions had appeared on the right 
internal canthus. Rapid variations of these lesions are typical characteristic of 
amyloidosis. 
The macroglossia presented yellowish red firm nodules on the dorsal side with 
lateral indentations corresponding to teeth position (Fig 18). Ventral face of the 
tongue showed yellowish white nodules with subcutaneous hemorrhages (Fig 19 and 
20). The buccal mucosa had submucosal hemorrhages present with nodules as well 
as frictional keratosis probably of traumatic origin (Fig 21). 
The histopathological examination of a lingual biopsy revealed an important 
infiltration of the musculature by interstitial diffuse amyloid. Congo red staining 
showed typical apple-green birefringement with polarized light (Fig 22).  
The patient had refused further examination. She was later hospitalized for cardiac 
insufficiency. Her state of health was reassessed with further testing. Repeated 
electrophoresis revealed large quantities of IgG λ light chain in the blood and urine. 
A bone marrow biopsy revealed the presence of abnormal plasma cells that reacted 
positive with anti- λ IgG antibodies. Stage IIIA MM was then diagnosed. 
The patient died from heart failure seven months after diagnosis of amyloidosis. 
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Fig 17 :  Well-defined subcutaneous haemorrhage associated with amyloidosis 
              located on upper eyelid and internal canthus. 
 
 
                
 
                                                  
 
 
Fig 18 : Amyloid infiltrations of the tongue leading to macroglossia. Note various 
               sized dark red nodules on dorsal side of the tongue. 
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Fig 19 : Lingual amyloidosis with ulceration. 
 
 
 
 
                          
 
Fig 20 : Macroscopic view of raised papules and nodules on the dorsum of 
              the tongue. 
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Fig 21 : Inner right buccal mucosa showing nodules. 
 
 
 
                                      
 
 
Fig 22 : Microscopic view of the tongue biopsy under polarized light. Note the 
              apple green appearance of amyloidal fibrils (x10). 
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8.3 Third case 
 
The following case was obtained through an internet discussion group47.  Mrs. J.H., a 
41 year-old woman had consulted her dentist for occasional numbness around the 
left lower lip. Less than 2 months later she had worsening pain which increased at 
night and was associated with  tooth #38. An orthopantogram (Fig 23 and 24) 
revealed a large radiolucency around the left third molar tooth. The oral mucosa 
appeared normal. 
Radiologically the patient had additional lytic skeletal lesions. Asides the use of anti-
inflammatory medication, the patient medical history was unremarkable. 
The patient was referred to an oral maxillo facial surgeon that removed the tooth 38 
as well as 70 to 80% of the associated fibrous mass which was discovered during 
surgery.  
The blood smear revealed a slight increase in rouleaux formation. The red blood 
cells were normal in number and normochromic. The bone marrow biopsy showed 
mild marrow lymphocytosis, adequate sideroblast iron and storage iron and 
peripheral  blood without specific histologic abnormalitites. The histopathological 
report revealed a malignant B-cell neoplasm consistent with plasmacytoma or MM. 
The laboratory results of the SPEP appeared normal and there were no monoclonal 
immunoglobulins detected in the  immunofixation. This lead to the diagnostic of 
stage III A non-secretory myeloma. The patient underwent first autologous  
hematopoietic progenitors cells transplants and chemotherapy with melphalan  and 
the second AHPC transplants 6 months later, after conditioning with melphalan and 
cyclophosphamide. A biopsy taken of a compressed fracture of L5 was negative for 
malignancy. The metastatic bone survey remained unchanged. She is presently on 
90 mg monthly of Aredia ®. The follow-up at 2 years showed that the patient was in 
hematologic and bone marrow complete remission with minimal abnormality on the 
MRI with no evidence of any recurrence.  
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Fig 23 : Orthopantogram showing lower left radiolucency in premolar and  
              molar region. 
 
 
 
      
 
Fig 24 : Detailed view of osteolytic lesion. Note ill-defined radiolucent borders 
               and associated root resorbtion. 
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9. Discussion 
 
Oral lesions may be the first manifestation of MM. The potential clinical symptoms, 
which are listed on Tab 1, are important awareness signs in the diagnosis and 
patient management. The lesions are more frequent in the mandible than the maxilla 
as there is a higher hematopoeisis36. 
It was estimated that if orthopantograms were systematically taken, the incidence of  
jaw involvement in MM would be higher23,77. Proper radiographic analysis may 
prevent an emergency bleeding condition during dental therapy by establishing a 
proper treatment planning, as bony changes may be pathognomonic of underlying 
diseases46. 
It is important to recognize that lymphoproliferative disorders such as MM may have 
little or no widespread lesions and may primarily manifest itself in the jaws4. 
Oral lesions may originate from the erosion of bone plate by the tumor. The lesions 
may present itself as a rubbery expansion of the jaw. It may be covered by the 
mucosal or be ulcerated inflammation due to chronic trauma76. Gingival bleeding 
associated with lesions may mimic periodontal or dental abscess. Extensive bleeding 
resulting from a minor surgical procedure was reported to have lead to the diagnosis 
of MM49.  
The diagnosis of MM requires a clinical, hematological, histological, radiological and 
biochemical examinations. Biopsies and histological examination are also used in 
differential diagnostic of plasma cell granuloma lesion  (rare exophytic lesion of the 
gingival) from soft-tissue myeloma (plasmacytomas) which may represent early 
stages of MM1 . 
Radiologically, MM resembles a common dental benign inflammatory infection such 
as a periapical granuloma or dental cyst. When the lesions are more destructive 
causing large bone resorptions, other intramedullary bone pathologies such as giant 
cell granuloma or even a malignancy (i.e. metastatic carcinoma) should be 
considered in the differential diagnosis. 
The radiological differential diagnosis should also include, ameloblastoma, 
osteoporosis, Langerhans’ cell histocytosis, bone lesions of hyperparathyroidism and 
osteomalacia. 
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Typical oral manifestations of MM were present in all three case that we have 
reported. The first patient, Mrs. D.M., suffered from what appeared to be a common 
palatal abscess by her general physician. Histological examination revealed a 
gingival location of myeloma. This is apparently an unusual location according to 
found literature. Numerous described oral lesions seem to be associated with the 
lower jaws rather than a palatal location. Palatal enlargement or swelling have also 
been described by others13,27,29,36,70. 
Two other buccal lesions were discovered, although asymptomatic, they were 
related to underlying radiolucencies. 
Further investigation of the latter was not completed, as patient general health did 
not permit it. 
 
The second patient, Mrs. J. D., suffered from macroglossia due to important amyloid 
infiltration. As seen in Fig 18, 19, 20 and 21, the extent of the affection involved the 
tongue and buccal mucosa, which provoked frictional keratosis due to local 
masticatory trauma. The lateral borders of the tongue showed dental indentations, 
which reproduced adjacent teeth. 
Subcutaneous hemorrhages and macroglossia lead to the discovery of amyloidosis 
and hence the diagnosis of MM. Amyloidosis had evolved for at least 2 to 3 years 
before the disease’s identification. The patient suffered from undiagnosed carpal 
tunnel syndrome which may have lead to an earlier discovery of MM if it had been 
biopsied. The patient’s impaired health did not permit further treatment of lingual 
amyloidosis. She had deceased shortly after detecting oral lesions. Miyoshi and 
Tagucchi45 have described a case with the same tongue and cardiac 
manifestations45. According to the literature cited in Tab 7, it seems that 
macroglossia due to amyloid infiltration, is regularly found as the most common oral 
manifestation of MM.  
 
The third case, Mrs. J.H. presented herself to her dentist complaining of a mobile 
painful tooth40 associated with numbness of lower lip. The patient was referred to a 
maxillofacial surgeon who removed the tooth and the surrounding tumor. The mass 
was described as a grey gelatinous mass surrounding the erupted tooth. The molar 
tooth exhibited apparent resorption of portions of the root apex. The orthopantogram 
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shows the importance of the lytic lesion (Fig 22). This case is very similar to those 
reported by Dhanrajani and Abdulkarim11 and Epstein et al.13.  
All three cases are of interest as they all show typical manifestations of MM. In which 
various oral lesions occur separately or side by side and not necessarily associated. 
In the two of the presented cases, MM manifested itself through oral mucosal 
lesions.  
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10. Conclusion 
 
To date no single cause has been identified in the etiology of MM. The latter may be 
the result of several risk factors acting together (radiation, chemicals, genetic factors, 
impaired immune system, etc.). The consequential malignant plasma cells will 
propagate and provoke systemic and local manifestations. 
 
Upon discovery of oral lesions, the disease’s course is often advanced which 
renders treatment difficult. It is important to constantly evaluate patients state of 
health in order to establish proper treatment keeping into consideration the resulting 
patients quality of life. Two case reports are described in which the oral lesions were 
not treated as both deceased shortly after diagnosis of their oral manifestations.  
As described above, the third case reports a complete remission at a two years 
evaluation after removal of oral lesion, two AHPC transplants and chemotherapy. 
Oral manifestations of MM are discovered in late stages of the disease. Oral 
manifestations in MM are not uncommon and may be the first sign or expression of 
the systemic disease leading in some cases, to the discovery of the disease. 
The role of the dentist becomes increasingly important as the general practitioner is 
often unfamiliar with oral lesions. An early diagnosis of MM may increase the 
patient’s response and outcome of therapy. 
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